Evidence map›Paper›PMID 42035083›Full record

ArticleJournal of translational medicine2026

Analysis of the tumor reactivity of autologous TILs and allogeneic γδ T cells via tumor organoid-immune cell coculture.

Zijun Su, Haishan Li, Dongdong Zhang, Nanxi Shi, Chanchan Song, Yu Huang, Weili He, Zhinan Yin, Liangping Li

Abstract read
In one paragraph

Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zijun SuSchool of Medicine, Jinan University, Guangzhou, 510632, China.
Haishan LiClinical Laboratory, Zhongshan Boai Hospital, Zhongshan, Guangdong, 528400, China.
Dongdong ZhangDepartment of Thoracic Surgery, The First Affiliated Hospital, Jinan University, Guangzhou, China.
Nanxi ShiThe College of Life Science and Technology, Jinan University, Guangzhou, 510632, China.
Chanchan SongInstitute of Clinical Oncology, Research Center of Cancer Diagnosis and Therapy, and Department of Clinical Oncology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Yu HuangThe Biomedical Translational Research Institute, Key Laboratory of Viral Pathogenesis & Infection Prevention and Control, School of Medicine, Jinan University, Guangzhou, 510632, China.
Weili HeDepartment of Breast Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China. heweili@jnu.edu.cn.
Zhinan YinGuangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai People's Hospital, Zhuhai Institute of Translational Medicine, Zhuhai Medical College of Jinan University, Zhuhai, 519000, China. tzhinan@jnu.edu.cn.
Liangping LiInstitute of Clinical Oncology, Research Center of Cancer Diagnosis and Therapy, and Department of Clinical Oncology, The First Affiliated Hospital of Jinan University, Guangzhou, China. liangping_li@jnu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe efficacy of conventional αβ T cell-based immunotherapies is often limited by tumor immune evasion. γδ T cells can bypass these limitations through MHC-independent tumor recognition, but their function within the tumor microenvironment (TME) remains poorly characterized due to a lack of relevant preclinical models. This study aims to establish a patient-derived tumor organoid-immune cell coculture system to evaluate γδ T-cell reactivity and cytotoxicity in a human-relevant TME (n = 10 PDTO lines; n = 3 independent experiments).

methodsWe developed an innovative coculture system—believed to be the first to integrate patient-derived tumor organoids (PDTOs) and autologous tumor-infiltrating lymphocytes (TILs) or healthy donor-derived allogeneic Vγ9Vδ2 T cell. T-cell activation was quantified by comparing CD137 expression on γδ T cells versus CD4+ and CD8+ T cells via flow cytometry after coculture. The cytotoxicity of Vγ9Vδ2 T cells was evaluated at various effector-to-target (E:T) ratios using a live-cell imaging assay to track BCO infiltration and apoptosis over 24 hours. Secreted effector molecules (IFN-γ, granzyme B, perforin) were measured from coculture supernatants using a cytometric bead array.

resultsBaseline analysis revealed that γδ T cells represent the most reactive subset within expanded TILs, with 12.3% expressing CD137 compared to 3.49% of CD8+ T cells (p = 0.0118). Notably, autologous BCO–TIL coculture preferentially enhanced γδ T-cell activation, reaching 24.85% CD137+—a frequency significantly higher than that of CD8 (9.15%, p = 0.0062) and CD4 (9.99%) subsets. The net increase in CD137 positivity for γδ T cells was more than double that of CD8 T cells (12.55% vs. 5.66%, p = 0.0467). Allogeneic Vγ9Vδ2 T cells demonstrated significant, dose-dependent cytotoxicity against BCOs (p < 0.0001). Maximal cell death (RFU fold-change: 5.2 ± 0.5) was achieved at an effector-to-target (E:T) ratio of 10:1 (p < 0.0001). This cytotoxic efficacy was highly correlated with the secretion of lytic effectors, including IFN-γ ( > 1000 pg/mL; p< 0.001), granzyme B ( > 2000 pg/mL), and perforin ( > 350 pg/mL).

conclusionOur findings demonstrate that 3D autologous coculture leads to the preferential stimulation of γδ T cells, establishing them as a primary reactive subset capable of bypassing MHC-restriction bottlenecks. The potent dismantling of tumor architecture by allogeneic Vγ9Vδ2 T cells, supported by high-resolution kinetic and cytokine data, substantiates their development as “off-the-shelf” therapies. Collectively, this platform provides a standardized, high-fidelity engine for the rapid preclinical assessment of next-generation cellular immunotherapies.

Indexed as

Allogeneic CellsLymphocytes, Tumor-InfiltratingNeoplasmsOrganoidsReceptors, Antigen, T-Cell, gamma-deltaCell Line, TumorCoculture TechniquesCytotoxicity, ImmunologicHumansLymphocyte ActivationTumor MicroenvironmentReceptors, Antigen, T-Cell, gamma-deltaCoculture modelsImmunotherapyTumor-infiltrating lymphocytes (TILs)Tumor microenvironment (TME)Tumor organoidsVγ9Vδ2 T cellsγδ T cells

Identifiers

PMID42035083
PMCPMC13123169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.